← Back to screener

Vanda Pharmaceuticals Inc. VNDA

Rank #866 · Nasdaq · $0.2B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
57.3
P/E
90.8
P/B
0.43
ROE
0.5%
Op. Margin
-7.2%
Debt Ratio
22%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Good

P/E 90.8x, P/B 0.43x. Ranks in the top 32% of the universe.

Profitability ★☆☆☆☆
Weak

ROE 0.5%. Ranks in the top 72% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 22%. Ranks in the top 14% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 24.3% year over year. Ranks in the top 93% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–381
2012–$0.0B$0.0B$0.0B–648
2013$0.0B$-0.0B$-0.0B$0.0B-34.2333
2014$0.0B$-0.0B$-0.0B$0.0B-89.2296
2015$0.0B$-0.0B$-0.0B$0.0B-62.6110
2016$0.1B$0.0B$0.0B$0.0B40.0181
2017$0.1B$-0.0B$-0.0B$0.2B-36.649
2018$0.1B$-0.0B$-0.0B$0.1B-12.756
2019$0.2B$-0.0B$-0.0B$0.1B-10.243
2020$0.2B$0.0B$0.0B$0.1B11.355
2021$0.2B$0.0B$0.1B$0.3B10.029
2022$0.2B$0.0B$0.0B$0.4B11.022
2023$0.3B$0.0B$0.0B$0.5B15.724
2024$0.3B$0.0B$0.0B$0.5B2.521
2025$0.2B$-0.0B$0.0B$0.5B-7.222

← See the full screener